Filing Analysis
VolitionRx issued common stock to Lind Global Asset Management XII LLC to satisfy payment obligations under a senior secured convertible promissory note. The issuance occurred in two tranches on May 19, 2026, and June 17, 2026.
🚩 Red Flags
- Use of convertible debt to fund operations often leads to significant shareholder dilution in micro-cap companies.
- The company is paying down debt with equity rather than cash, which may indicate liquidity constraints.
📋 Key Facts
- Issued 333,332 shares on June 17, 2026, to satisfy a $416,666 payment obligation.
- Issued 212,259 shares on May 19, 2026, to satisfy a $416,666 payment obligation.
- Shares were issued as part of a senior secured convertible promissory note with an original principal amount of $7,500,000.
- The counterparty is Lind Global Asset Management XII LLC.
- The issuance relied on exemptions Section 3(a)(9) or 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
VolitionRx Limited completed a public offering of 2,960,000 shares of common stock and 1,480,000 accompanying warrants at a combined price of $1.55 per share and warrant. The offering closed on June 9, 2026, raising approximately $4.1 million in net proceeds.
🚩 Red Flags
- Use of proceeds includes the repayment of existing secured convertible notes, which may indicate pressure from debt holders.
- Dilution from the issuance of nearly 3 million shares and 1.48 million warrants.
📋 Key Facts
- Net proceeds from the offering are approximately $4.1 million.
- Potential additional gross proceeds from full exercise of warrants: $2.3 million.
- Offering price: $1.55 per Share and accompanying Warrant.
- Warrants have a 5-year term and an exercise price of $1.55.
- Proceeds are earmarked for research, product development, clinical studies, commercialization, working capital, and repayment of secured convertible notes.
- Maxim Group LLC served as the placement agent with a $75,000 reimbursement for out-of-pocket expenses.
VolitionRx Limited (VNRX) entered into a waiver and consent agreement with Lind Global Asset Management XII LLC on May 21, 2026, after the company breached a Market Capitalization Covenant on its two outstanding senior secured convertible promissory notes totaling $9.9M in original principal. While Lind waived acceleration and foreclosure rights stemming from the covenant breach, the violation triggered a 10% penalty on outstanding principal balances and grants Lind enhanced conversion rights at a discount to market price. This filing signals significant financial stress and potential dilution risk for existing shareholders.
🚩 Red Flags
- Market capitalization covenant breach signals the company's market cap has fallen to distressed levels relative to its debt obligations
- 10% penalty on outstanding principal of BOTH notes adds a material incremental liability (estimated ~$990,000 based on original principals of $9.9M combined)
- Enhanced conversion price mechanism — at 90% of average of 3 lowest VWAPs over 20 trading days — creates significant dilution pressure at discounted prices
- Notes are SENIOR SECURED, meaning Lind holds collateral claims over company assets in any default scenario
- Waiver is narrowly scoped: only covers Market Capitalization Covenant; all other default triggers remain active
- Lind retains preserved rights under the Notes as explicitly carved out in the Waiver, indicating ongoing covenant risk
- Inability to maintain minimum market cap suggests deteriorating equity value and potential ongoing financial distress
- Discounted conversion rights effectively create a 'death spiral' financing dynamic if stock continues to decline
📋 Key Facts
- Company breached the Market Capitalization Covenant under two senior secured convertible promissory notes held by Lind Global Asset Management XII LLC
- Note 1 (2025 Note): $7,500,000 original principal, issued May 15, 2025
- Note 2: $2,400,000 original principal, issued January 7, 2026 under amended and restated securities purchase agreement
- Total original principal across both Notes: $9,900,000
- Waiver and Consent executed May 21, 2026, filed May 22, 2026
- Covenant breach triggered a 10% penalty on the Outstanding Principal Amount of EACH Note
- Lind waived rights to declare amounts due, demand immediate payment, accelerate obligations, or foreclose on collateral arising from this specific covenant breach
- Lind retains right to convert outstanding principal into common stock at the LOWER of: (i) then-current Conversion Price, or (ii) 90% of the average of the three lowest VWAPs over the 20 prior trading days
- Conversion is subject to a 4.99% beneficial ownership cap
- Notes are senior secured, meaning Lind holds a security interest in company assets
- Waiver document will be filed as exhibit to 10-Q due no later than August 14, 2026
- Common stock trades on NYSE American under ticker VNRX
Mickie Henshall notified the Board of VolitionRx Limited on May 12, 2026, that she will not stand for re-election at the 2026 Annual Meeting of Stockholders. Following her departure, the Board will reduce its size from eight to seven directors.
📋 Key Facts
- Director Mickie Henshall notified the Board of her decision not to stand for re-election on May 12, 2026.
- Ms. Henshall has served as a director since August 2022.
- The Company stated there were no disagreements regarding operations, policies, or practices.
- The Board of Directors will be reduced from eight to seven members effective immediately prior to the 2026 Annual Meeting.
VolitionRx Limited announced its financial results for the first quarter ended March 31, 2026, and scheduled a conference call to discuss business updates.
📋 Key Facts
- Released Q1 2026 financial results for the period ended March 31, 2026
- Scheduled a conference call for May 15, 2026, at 8:30 a.m. U.S. Eastern Time
- The report was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The filing includes a press release as Exhibit 99.1
VolitionRx Limited has implemented a 1-for-20 reverse stock split of its common stock, effective April 28, 2026. The action follows stockholder approval granted on March 31, 2026, and involves an amendment to the company's Certificate of Incorporation.
🚩 Red Flags
- Reverse stock split (1-for-20 ratio) is a significant consolidation often used to maintain exchange listing requirements.
- The high ratio (1:20) suggests the share price had likely fallen significantly below the $1.00 minimum bid price threshold common for NYSE American or Nasdaq listings.
📋 Key Facts
- The reverse stock split ratio is set at 1-for-20.
- The split became effective at 12:01 a.m. ET on April 28, 2026.
- A Certificate of Third Amendment was filed with the Delaware Secretary of State on April 27, 2026.
- The Board of Directors determined the specific ratio within a range previously authorized by stockholders.
- The split affects the treatment of fractional shares, though specific cash-out or rounding terms were not detailed in the summary text.
VolitionRx Limited received notification from NYSE American that its plan to regain compliance with listing standards has been accepted. The company is currently in violation of stockholders' equity requirements due to persistent net losses and has until August 6, 2027, to meet the minimum equity thresholds.
🚩 Red Flags
- Reported net losses in five most recent fiscal years.
- Stockholders' equity has fallen below the $2.0 million, $4.0 million, and $6.0 million tiered requirements.
- Potential for delisting proceedings if periodic milestones in the compliance plan are not met.
📋 Key Facts
- NYSE American accepted the company's compliance plan on April 22, 2026.
- The company has been granted a 'Plan Period' until August 6, 2027, to regain compliance.
- The company is in violation of Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.
- The company failed to maintain minimum stockholders' equity of $6.0 million despite reporting net losses in its five most recent fiscal years.
- The company is not currently eligible for the $50 million market capitalization exemption.
VolitionRx Limited has announced a 1-for-20 reverse stock split of its common stock, effective April 28, 2026. The split is being implemented to satisfy terms within financing agreements with Lind Global Asset Management XII LLC.
🚩 Red Flags
- Significant 1-for-20 reverse stock split, often a sign of share price weakness.
- The split is explicitly linked to financing terms with Lind Global Asset Management, suggesting restrictive covenants or pressure from institutional lenders.
📋 Key Facts
- The reverse stock split ratio is set at 1-for-20.
- The split is expected to become effective at 12:01 a.m. ET on April 28, 2026.
- The action follows shareholder approval granted at a special meeting on March 31, 2026.
- The split is necessitated by financing documents with Lind Global Asset Management XII LLC dated May 20, 2025, and January 15, 2026.
- No fractional shares will be issued; instead, fractional entitlements will be rounded up to the next whole share.
VolitionRx stockholders approved a reverse stock split and a significant share issuance to Lind Global Asset Management. The reverse split ratio is authorized between 1-for-5 and 1-for-20, while the share issuance exceeds 20% of the company's outstanding common stock.
🚩 Red Flags
- Approval of a reverse stock split, typically a defensive measure to maintain exchange listing requirements.
- Significant dilutive event involving the issuance of more than 20% of the company's equity to a single institutional investor (Lind Global Asset Management).
📋 Key Facts
- Special meeting of stockholders held on March 31, 2026.
- Stockholders approved a reverse stock split with a ratio ranging from 1-for-5 to 1-for-20.
- Approval granted for the issuance of common stock exceeding 20% of outstanding shares to Lind Global Asset Management XII LLC.
- As of the February 9, 2026 record date, there were 135,565,326 shares of common stock outstanding.
- The share issuance was required to comply with NYSE American Rule 713.
VolitionRx Limited announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a conference call for April 1, 2026, to discuss these results and provide business updates.
📋 Key Facts
- Financial results released for the fiscal year ended December 31, 2025
- Conference call scheduled for April 1, 2026, at 8:30 a.m. U.S. Eastern Time
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- Press release dated March 31, 2026, was included as Exhibit 99.1
VolitionRx Limited is repaying a $7.5M senior secured convertible note held by Lind Global Asset Management by issuing massive quantities of common stock at deeply discounted prices (~$0.21-$0.23/share). In roughly one month, the company issued 6,419,867 shares to satisfy just $1,416,666 in repayment obligations, representing a classic toxic convertible ("death spiral") financing structure that severely dilutes existing shareholders.
🚩 Red Flags
- Toxic convertible note structure — Lind Global is a well-known provider of death spiral financing to micro-cap companies, where conversion prices decline with the stock, creating relentless dilution
- Massive dilution: 6.4M+ shares issued in one month to satisfy only ~$1.4M of a $7.5M obligation; at this rate, tens of millions more shares may be required to fully retire the note
- Extremely low implied conversion prices ($0.213-$0.227/share) suggest the stock is trading near penny-stock levels, raising NYSE American continued listing compliance risk
- The SPA was amended and restated on January 7, 2026, just 8 months after the original agreement — may indicate deteriorating terms or company difficulties
- Senior secured status of the note means Lind has priority claim over all company assets in a default scenario
- Additional overhang from 483,870 warrants at $0.682 exercise price from the September 2025 private placement
- Repeated unregistered issuances to a single institutional lender indicates dependence on dilutive financing
📋 Key Facts
- $7,500,000 senior secured convertible promissory note issued to Lind Global Asset Management XII LLC under SPA dated May 15, 2025 (amended/restated January 7, 2026)
- Feb 17, 2026: 1,956,178 shares issued to satisfy $416,666 payment (~$0.213/share implied price)
- Jan 29, 2026: 2,569,753 shares issued to satisfy $583,334 payment (~$0.227/share implied price)
- Jan 16, 2026: 1,893,936 shares issued to satisfy $416,666 payment (~$0.220/share implied price)
- Total: 6,419,867 shares issued in ~1 month to repay only $1,416,666 of the $7.5M note
- Separate private placement on Sep 18, 2025: 483,870 shares + 483,870 warrants (exercise price $0.682) for $300,000 ($0.62/share combined price)
- Warrants from September placement expire September 18, 2030
- Note is senior secured, giving Lind priority claim on company assets
- All issuances made under Section 3(a)(9), 4(a)(2), and/or Rule 506 of Reg D exemptions